MDS Clinical Trials in New York, New York
11 recruitingNew York, New York
Showing 1–11 of 11 trials
Recruiting
Phase 1
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
Acute Myelogenous LeukemiaMyelodysplastic Syndromes (MDS)
Beijing InnoCare Pharma Tech Co., Ltd.266 enrolled18 locationsNCT06656494
Recruiting
Phase 3
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
Myelodysplastic Syndromes (MDS)Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS)
Institut de Recherches Internationales Servier48 enrolled62 locationsNCT06465953
Recruiting
Phase 2
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
LymphomaMyelofibrosisAML (Acute Myelogenous Leukemia)+8 more
Center for International Blood and Marrow Transplant Research358 enrolled13 locationsNCT06859424
Recruiting
Phase 2
Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders
AMLMDSHLH+6 more
Memorial Sloan Kettering Cancer Center31 enrolled1 locationNCT04644016
Recruiting
Phase 1
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Myelodysplastic Syndrome (MDS)Relapsed/Refractory Acute Myeloid Leukemia (AML)
Cullinan Therapeutics Inc.60 enrolled11 locationsNCT05143996
Recruiting
Phase 1
Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics
Myelodysplastic Syndrome (MDS)Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)Acute Myeloid Leukaemia (AML)
medac GmbH36 enrolled4 locationsNCT05534620
Recruiting
Phase 3
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
Myelodysplastic Syndromes (MDS)
Celgene665 enrolled143 locationsNCT04064060
Recruiting
Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
Fanconi AnemiaSevere Marrow FailureMyelodysplastic Syndrome (MDS)+1 more
Children's Hospital Medical Center, Cincinnati70 enrolled3 locationsNCT02143830
Recruiting
Phase 1
Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML
MDSAML, Adult
Stelexis BioSciences125 enrolled13 locationsNCT06533761
Recruiting
A Long Term Follow-up Study of TScan TCR-T Products
AMLMDSALL
TScan Therapeutics, Inc.1,000 enrolled2 locationsNCT06976736
Recruiting
Phase 1
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Hodgkin LymphomaAMLMDS+8 more
Therapeutic Advances in Childhood Leukemia Consortium54 enrolled31 locationsNCT05476770